Changing life sciences, one droplet at a time.
We are harnessing the hidden power of sound to revolutionize drug delivery.
.png)
WHAT WE DO
Drug delivery, simplified.
We are improving the care of millions of patients by formulating new and existing biologic products, traditionally administered through lengthy hospital-based intravenous injections,
into ultra highly concentrated subcutaneous
injections that are as simple as a flu shot.
.png)
Our platform brings
life-saving drug delivery
from the hospital to your home.
Why subcutaneous delivery?
.png)
Why aren't more products like this?
As monoclonal antibodies (mAbs) approach the high concentrations necessary for small-volume subcutaneous delivery, they become increasingly viscous and unstable, making them extremely difficult to process, manufacture, and inject. Consequently, fewer than 50% of mAbs are available in subcutaneous form - limited to those requiring small doses or large injection volumes. This problem becomes even more challenging for new biotherapeutics, including antibody-drug conjugates (ADCs), bispecifics, and fusion proteins.
Every day, thousands of patients make the arduous journey to hospitals or infusion centers for their life saving therapies. Once there, they face a long and uncomfortable intravenous (IV) treatment, which burdens hospital resources, healthcare professionals, and the patients themselves. At AcousticaBio, we believe there's a better way to deliver these life-saving therapies - through subcutaneous administration. It's no surprise that the overwhelming majority of patients prefer subcutaneous injections over IV treatments - and for good reason! These formulations unlock significant benefits for patients, drug manufacturers, and the healthcare system as a whole.
We create ultra-high concentrations of biologics, exceeding 400 mg/mL.
Our microparticle suspension formulations are designed to achieve the optimal concentrations and characteristics necessary for effective subcutaneous delivery.
OUR TECHNOLOGY
By leveraging advanced manufacturing, we can improve the delivery of novel therapeutics.
-Daniele Foresti, Founder
OUR SOLUTION DELIVERS
Easier injections
Painless subcutaneous injections allow for self-administration.
Safer access
Better drug delivery means less severe immune responses.
Reduced cost
Increased savings for patients, providers, and pharmaceutical companies alike.
Low viscosity
Particle suspensions allow us to overcome the viscosity
limitation.
Less aggregation
mAbs are stabilized within a polymer matrix resulting in less antibody aggregation.
Greater stability
Higher payload concentrations are encapsulated.
IN THE NEWS
ARPA-H Investor Catalyst Hub | October 2024
.png)
Follow us for updates